Journal Information
Vol. 14. Issue 3.
Pages 319-321 (May - June 2010)
Share
Share
Download PDF
More article options
Vol. 14. Issue 3.
Pages 319-321 (May - June 2010)
Brief communication
Open Access
Methemoglobinemia and dapsone levels in patients with leprosy
Visits
2292
Jose Luiz Fernandes Vieira1,
Corresponding author
jvieira@ufpa.br

Correspondence to: Laboratório de Toxicologia, Universidade Federal do Pará Rua Augusto Corrêa, 1 Belém – PA – Brazil.
, Juan Gonzalo Bardarez Riveira2, Ana de Nazaré Silva Martins2, Jorge Pereira da Silva1, Claudio Guedes Salgado1
1 Toxicology Professor of Universidade Federal do Pará Pharmacy School, Belém, PA, Brazil
2 Undergraduated students of Universidade Federal do Pará, Belém, PA, Brazil
This item has received

Under a Creative Commons license
Article information
Abstract

The objective of this work was to determine the methemoglobinemia and correlate with dapsone levels in multibacillary leprosy patients under leprosy multi-drug therapy. Thirty patients with laboratory and clinical diagnosis of multibacillary leprosy were enrolled. Dapsone was analyzed by high performance liquid chromatography and methemoglobinemia by spectrophotometry. The mean dapsone concentrations in male was 1.42 g/mL and in female was 2.42 g/mL. The mean methemoglobin levels in male was 3.09 μg/mL; 191%, and in female was 2.84 ± 1.67%. No correlations were seen between dapsone levels and methemoglobin in male and female patients. Our results demonstrated that the dosage of dapsone in leprosy treatment does not promote a significant methemoglobinemia.

Keywords:
methahemoglobinemia
dapsone
leprosy
Full text is only aviable in PDF
References
[1.]
I.Y. Zhu, M.J. Stiller.
Dapsone and sulfones in dermatology: overview and update.
J Am Acad Dermatol, 45 (2001), pp. 420-434
[2.]
M.D. Coleman.
Dapsone toxicity: some current perspective.
Gen Pharmacol, 26 (1995), pp. 1461-1467
[3.]
J. Zuidema, E.S.M. Hilbers-Modderman, F.W.H.M. Merkus.
Clinical pharmacokinetics of dapsone.
Clin Pharmacokinet, 11 (1986), pp. 299-315
[4.]
N.K.D. Halim, E. Ogbeide.
Haematological alterations in leprosy patients treated with dapsone.
East Afr Med J, 79 (2002), pp. 100-102
[5.]
I. Kaur, M. Metha, N. Agnihotri, et al.
Dapsone-induced methemoglobinemia in leprosy patients.
Int J Lepr, 69 (2001), pp. 247-249
[6.]
C. Vage, N. Saab, P.M. Woster, C.K. Svensson.
Dapsone-induced hematologic toxicity: comparison of the methemoglobin-forming ability of hydroxylamine metabolities of dapsone in rat an human blood.
Toxicol Appl Pharmacol, 129 (1994), pp. 309-316
[7.]
T.R. Reilly, P.M. Woster, C.K. Svensson.
MMethemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: implications for differences in adverse Drug Reactions.
J Pharmacol Exp Ther, 288 (1999), pp. 951-959
[8.]
E. Hegesh, R.N. Gruener, R. Bockwosky, H.J. Shuvat.
A sensitive micromethod for the determination of methemoglobin in blood.
Clin Chim Acta, 30 (1970), pp. 679-682
[9.]
S. Kwadijk, J.S. Torano.
High-performance liquid chromatographic method with ultraviolet detection for the determination of dapsone and its hydroxylated metabolite in human plasma.
Biomed Chromatogr, 16 (2002), pp. 203-208
[10.]
G. Ab, J.M. Brocavich, J.V. Etzel, et al.
Evaluation of effects of altered gastric pH on absorption of dapsone in healthy volunteers.
Antimicrob Agents Chemoter, 38 (1994), pp. 2227-2229
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved
The Brazilian Journal of Infectious Diseases
Article options
Tools